Literature DB >> 2600979

Biologic characteristics of an immunosuppressive factor derived from a human lung cancer cell line.

R D Wang, Z C Chen, Y Luo, Z H Feng.   

Abstract

A 549, a human lung cancer cell line, spontaneously produces a tumor-derived immunosuppressive factor (TDSF) which inhibited PHA-stimulated T lymphocyte proliferation via a noncytotoxic mechanism. The inhibition increased in a dose-dependent pattern. The factor also markedly suppressed production of interleukin (IL-2) by PHA-stimulated lymphocytes and IL 2-dependent proliferation of activated lymphocytes. The fact that TDSF possessed very potent inhibitive action on IL-2 is especially noteworthy if we consider the use of IL-2 as immunotherapeutic agent. The synthesis of the factor was inhibited by mitomycin C, actinomycin D and cycloheximide, indicating that the factor is a genic product of A 549 cells. The factor is chemically a protein with a molecular weight greater than 150 KD and sensitive to extremes of pH, heating to 60 degrees C and trypsin treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2600979     DOI: 10.1007/bf02908961

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  6 in total

1.  Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer.

Authors:  A H Glasgow; R B Nimberg; J O Menzoian; I Saporoschetz; S R Cooperband; K Schmid; J A Mannick
Journal:  N Engl J Med       Date:  1974-12-12       Impact factor: 91.245

2.  Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro.

Authors:  J Werkmeister; R Zbroja; W McCarthy; P Hersey
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

3.  Characterization of an immunosuppressive factor derived from colon cancer cells.

Authors:  E C Ebert; A I Roberts; S M O'Connell; F M Robertson; H Nagase
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

4.  Nonspecific immunosuppressive factors in malignant ascites: further characterization and possible relationship to erythrocyte receptors of human peripheral T cells.

Authors:  S K Oh; F L Moolten
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

5.  Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.

Authors:  A Rey; B Klein; D Zagury; C Thierry; B Serrou
Journal:  Immunol Lett       Date:  1983-03       Impact factor: 3.685

6.  Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.

Authors:  A Fontana; H Hengartner; N de Tribolet; E Weber
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

  6 in total
  1 in total

1.  Effect of immunosuppressive factor produced by human lung cancer cell line A549 on the production and action of interleukin 1.

Authors:  Z H Feng; G M Zhang; T L Hao; Z C Chen; Z Y Jiang
Journal:  J Tongji Med Univ       Date:  1990
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.